← Research library

Chlorobenzoylaminoadamantane formulation for physical performance at high and low temperatures

Patent disclosure · 2019

What the patent describes
Animal experiments on a Chlodantane formulation under temperature stress; the cited result below is from the cold-exposure rotating-rod experiment.
Reported evidence
The patent reports longer treadmill endurance with the Chlodantane formulation under heat and cold. In heat, the selected comparison was 56.23 ± 5.36 versus 27.69 ± 1.31 minutes in controls. Ladasten showed a heat signal at the higher tested exposure but no significant cold-endurance benefit.

Cold-exposure motor coordination · 24.0 (17.0–33.0) s with the formulation versus 11.5 (9.5–15.5) s in cold-exposed controls · Medians and quartiles; intact animals 127.0 (100.5–183.0) s · p=0.04 versus cold control

Reported patent results

Reported findings

The formulation increased rod-retention time after cold stress but did not restore the intact-animal value.

Animal experiments on a Chlodantane formulation under temperature stress; the cited result below is from the cold-exposure rotating-rod experiment.

Population or model Animal experiments on a Chlodantane formulation under temperature stress; the cited result below is from the cold-exposure rotating-rod experiment.

Results · Description: final hypothermia/Rotarod experiment and narrative accompanying Table 5.
MeasureResultComparison, timing and statistics
Cold-exposure motor coordination24.0 (17.0–33.0) s with the formulation versus 11.5 (9.5–15.5) s in cold-exposed controlsMedians and quartiles; intact animals 127.0 (100.5–183.0) s · p=0.04 versus cold control
Sydnocarb comparator6.5 (5.0–9.0) s versus 11.5 (9.5–15.5) s cold controlWorse retention in this test; not general clinical inferiority · p=0.04

These findings concern a specific formulation and mouse model. They do not establish human occupational performance or protection under dangerous temperature exposure.

Source for these results ↗ · Reviewed 2026-11-06

Patent claims and provenance

Use. Later Chlodantane use claims; Bromantane served as a comparator.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
RU2704126C2 ↗ · 2019-10-24
Earliest priority / filing
2016-11-28 / 2016-11-28
Original applicant / assignee
Российская Федерация, от имени которой выступает Министерство обороны Российской Федерации
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
62557483 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Pharmaceutical composition based on chlorobenzoylaminoadamantane, which increases physical performance in high and low temperatures

Inventors: Сергей Борисович Середенин; Григорий Георгиевич Незнамов; Валерий Гаврилович Барчуков; Борис Михайлович Пятин; Нина Ивановна Авдюнина; Любовь Николаевна Грушевская; Надежда Михайловна Зайцева; Константин Викторович Алексеев; Евгения Викторовна Блынская; Анна Сергеевна Михеева; Людмила Михайловна Гаевая; Мария Сергеевна Сергеева; Сергей Александрович Крыжановский; Иосиф Борисович Цорин; Валерий Николаевич Столярук; Марина Борисовна Вититнова.

RU2704126C2

Original patent PDF ↗

Patent collection and status interpretation →

Study limitations and source details

Study limitations

  • Patent-reported animal results are not an independently replicated clinical trial or evidence of safe heat/cold exposure.
  • The response was non-linear; formulation-specific effects cannot be assigned to every Chlodantane product.
  • The groups were small, and the source gives conflicting comparison-group sizes.

Source details

Patent

Selected source passages checked; complete methods and risk of bias not appraised.

Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.

Sources checked

Citation

Patent / reported experimentsFull text available

Author unconfirmed. Chlorobenzoylaminoadamantane formulation for physical performance at high and low temperatures RU2704126C2; filed 28 November 2016

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards